SPH
SPH
A national pharmaceutical industry group headquartered in Shanghai
Shanghai Pharmaceutical Group Corporation Limited (the Company) (HKSE stock code: 02607; SSE stock code: 601607) is a national pharmaceutical industry group headquartered in Shanghai. The Company's main business covers pharmaceutical research and development and manufacturing, distribution and retailing, with an operating income of 105.5 billion yuan in 2015, the Company's overall ranking is among the best in China, and it is one of the few listed pharmaceutical companies in China with a leading position in both the pharmaceutical products and distribution markets, selected as a sample stock of the SSE 180 Index and the CSI 300 Index, and its H shares are selected as a constituent stock of the Hang Seng Index, a constituent stock of the Morgan Stanley China Index ( (MSCI).
- All
- News
- Analysis
- Research
Briefing May 24, 2022 09:04 AM
· Financials
Xuancheng, Anhui: the upper limit of the unified provident fund loan is 500000 yuan, and the number of talents is increased by 100000 yuan
In-depth
Nov 16, 2022 05:19 PM
Nov 07, 2022 04:27 PM
Aug 29, 2022 05:45 PM
Apr 22, 2021 03:11 PM
Consumer Staples, Healthcare, Technology
HastenPharma Secures USD 315 Mn in Financing to Focus on M&A Business and R&D
Anhui-based biopharmaceutical company HastenPharma(海森生物) raised USD 315 million in funding on April 20, with the financing round aimed at focusing on future mergers and acquisitions and product innovation, according to EqualOcean.
Apr 23, 2023 12:20 PM
Briefing Jul 19, 2021 04:38 PM
Fitch confirmed that Wanzhou International, the parent company of Shuanghui, is rated as' BBB + 'with a stable outlook.
See more
Related Companies
EqualOcean Analysis